Health ยท Democratic Republic of Congo
New Ebola Vaccine Trial Opens in Bunia as DR Congo Battles Record Outbreak
A clinical trial of candidate vaccines against Bundibugyo-virus Ebola has opened in Bunia, in DR Congo's Ituri Province. Known as TUMAiNi, it will enrol contacts of confirmed cases as the country faces what is described as its deadliest and fastest-growing Ebola outbreak, with more than 9,000 confirmed cases.
A clinical trial of new candidate vaccines against Ebola has begun in Bunia, in the Democratic Republic of Congo's Ituri Province, as the country struggles to contain what is described as the deadliest and fastest-growing Ebola outbreak in its history.
The trial, called TUMAiNi, was launched on Saturday. It will evaluate candidate vaccines against Ebola disease caused by the Bundibugyo virus, and will involve contacts of confirmed cases.
The study is led by the National Institute for Biomedical Research (INRB), Congo's national public health laboratory. The World Health Organization is providing technical, scientific and logistical support.
Ituri's governor, Major General Kasongo Gaby, described the launch as a significant moment in the response. He said it reflected a shared determination not to passively accept health threats but to mobilise all available resources.
The outbreak was declared in mid-May, and DR Congo has since confirmed more than 9,000 cases. The disease has also crossed borders. Kenya has reported nine cases, and Nigeria confirmed its first case this week. Uganda, which reported 20 cases, was declared Ebola-free in August.
The supplied information does not name the candidate vaccines being tested, say how many participants will be enrolled, or give a timeline for results. Other vaccination efforts are also under way in eastern Congo, but the trial is designed specifically to assess candidates against the Bundibugyo strain driving the current outbreak.